C4 Therapeutics’ Phase 2 Myeloma Trial Moves Forward, Setting Up a Key Catalyst for CCCC Investors

C4 Therapeutics, Inc. (CCCC) announced an update on their ongoing clinical study.

C4 Therapeutics Advances Phase 2 Myeloma Study, Drawing Investor Interest

Study Overview: C4 Therapeutics, Inc. is running a Phase 2 trial called “A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma.” The goal is to see how well this drug mix controls cancer in patients whose multiple myeloma has come back or stopped responding to prior treatment, while also tracking safety and how the drugs behave in the body. For investors, this study targets a large, established cancer market where even modest efficacy can be meaningful.

Intervention/Treatment: The study tests two oral drugs used together. Cemsidomide is the lead experimental pill designed to attack myeloma cells and improve disease control. Dexamethasone is a standard steroid used in many myeloma regimens to boost anti-cancer effects. Patients take cemsidomide once daily for 14 days on and 14 days off in a 28-day cycle, plus dexamethasone once a week. The aim is to create a convenient, all-oral regimen that can be used in hard-to-treat patients.

Study Design: This is an interventional Phase 2 study with one treatment group and no placebo or comparison arm. All participants receive the same combination of cemsidomide and dexamethasone. The trial is open-label, meaning doctors and patients know what is being given. The main purpose is treatment, not prevention or diagnosis, and the focus is on how many patients respond and how safe the regimen is over time.

Study Timeline: The study is listed as recruiting, indicating enrollment is active and data collection is underway. The trial record was first submitted on December 9, 2025, signaling when the sponsor formally moved into this Phase 2 setting. The most recent update to the listing was on January 14, 2026, which shows the sponsor is actively maintaining the record and likely refining details such as enrollment and site information. Primary and final completion dates have not been specified in the data provided, but investors should assume key readouts are still ahead and likely to be value-moving events.

Market Implications: For C4 Therapeutics (NASDAQ: CCCC), this study represents a key proof-of-concept opportunity in relapsed/refractory multiple myeloma, a crowded but high-value space dominated by players like Bristol Myers Squibb, Johnson & Johnson, and others. Positive signals on response rates or safety could support a higher valuation by validating the company’s approach in a well-known cancer setting and opening partnership or expansion options. Conversely, delays or weak results could weigh on sentiment given competition from existing drugs and newer cell and bispecific therapies. Near term, the fresh “recruiting” status and recent January 2026 update may support modest speculative interest, but most upside will depend on future data releases rather than this procedural update.

The study remains ongoing and updated, with further details available on the ClinicalTrials portal.

To learn more about CCCC’s potential, visit the C4 Therapeutics, Inc. drug pipeline page.